Institute of General and Molecular Pathology, Centre of Excellence for Translational Medicine, University of Tartu, Tartu, Estonia.
APMIS. 2012 Nov;120(11):857-71. doi: 10.1111/j.1600-0463.2012.02914.x. Epub 2012 May 15.
Primary biliary cirrhosis (PBC) is considered a model autoimmune disease based on several features, including the presence of a highly directed and very specific immune response to mitochondrial autoantigens, a female predominance, a targeted destruction of the biliary epithelium, and homogeneity between patients. It is essentially a chronic progressive cholestatic liver disease characterized by immune-mediated destruction of small- and medium-sized intrahepatic bile ducts. There is considerable variation in the incidence and prevalence of the disease between regions of the world, although such differences likely reflect not only a true disparity in disease but also differences in awareness; for example, in the United States, PBC is often detected in an asymptomatic stage based on multi-phasic clinical testing. There has been considerable progress at defining the immune response in this disease, including quantitation of autoreactive T cells against PDC-E2, the major mitochondrial autoantigen. The overwhelming data suggests that patients develop PBC based on a genetic predisposition and loss of tolerance to one or more environmental agents. In this review, we will present an updated overview of PBC and place it in the context of autoimmunity.
原发性胆汁性肝硬化(PBC)被认为是一种自身免疫性疾病模型,基于几个特征,包括存在针对线粒体自身抗原的高度定向和非常特异的免疫反应、女性优势、胆管上皮的靶向破坏以及患者之间的同质性。它本质上是一种慢性进行性胆汁淤积性肝病,其特征是免疫介导的中小肝内胆管破坏。尽管这种差异可能不仅反映了疾病的真正差异,还反映了认识上的差异,但世界各地该病的发病率和患病率存在相当大的差异;例如,在美国,PBC 通常在无症状阶段根据多相临床检测发现。在定义这种疾病的免疫反应方面已经取得了相当大的进展,包括定量检测针对 PDC-E2 的自身反应性 T 细胞,PDC-E2 是主要的线粒体自身抗原。压倒性的数据表明,患者基于遗传易感性和对一种或多种环境因素的耐受性丧失而患上 PBC。在这篇综述中,我们将介绍 PBC 的最新概述,并将其置于自身免疫的背景下。